Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer.
Lung Cancer
; 64(1): 124-6, 2009 Apr.
Article
em En
| MEDLINE
| ID: mdl-19008012
ABSTRACT
Pemetrexed is a multitargeted antifolate approved for the second-line treatment of locally advanced or metastatic non-small cell lung cancer. The combination of pemetrexed with gemcitabine has been studied in several clinical trials showing a promising antitumor activity with a mild toxicity profile. We present the case of a patient who experienced fever, arthralgia, skin rash and high serum ferritin levels after first cycle of this chemotherapy combination, compatible with an adult onset Still's disease. This adverse event has not been previously reported.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Doença de Still de Início Tardio
/
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article